Loading...
Protocol for the CONVERT trial-Concurrent ONce-daily VErsus twice-daily RadioTherapy: an international 2-arm randomised controlled trial of concurrent chemoradiotherapy comparing twice-daily and once-daily radiotherapy schedules in patients with limited stage small cell lung cancer (LS-SCLC) and good performance status.
Falk, Sally Ashcroft, Linda Bewley, Michelle Wilson, E Groom, N Snee, M Fournel, P Cardenal, F
Falk, Sally
Ashcroft, Linda
Bewley, Michelle
Wilson, E
Groom, N
Snee, M
Fournel, P
Cardenal, F
Citations
Altmetric:
Abstract
Concurrent ONce-daily VErsus twice-daily RadioTherapy (CONVERT) is the only multicentre, international, randomised, phase III trial open in Europe and Canada looking at optimisation of chemoradiotherapy (RT) in limited stage small cell lung cancer (LS-SCLC). Following on from the Turrisi trial of once-daily versus twice-daily (BD) concurrent chemoradiotherapy, there is a real need for a new phase III trial using modern conformal RT techniques and investigating higher once-daily radiation dose. This trial has the potential to define a new standard chemo-RT regimen for patients with LS-SCLC and good performance status.
Description
Date
2016
Publisher
Collections
Files
Loading...
Main article
Adobe PDF, 791.6 KB
Keywords
Type
Article
Citation
Protocol for the CONVERT trial-Concurrent ONce-daily VErsus twice-daily RadioTherapy: an international 2-arm randomised controlled trial of concurrent chemoradiotherapy comparing twice-daily and once-daily radiotherapy schedules in patients with limited stage small cell lung cancer (LS-SCLC) and good performance status. 2016, 6 (1):e009849 BMJ Open